Literature DB >> 3497222

Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen.

R M Pemberton, M J Cannon, P J Openshaw, L A Ball, G W Wertz, B A Askonas.   

Abstract

We examined the specificity of BALB/c cytotoxic T (Tc) cells for respiratory syncytial virus (RSV) components, using recombinant vaccinia viruses (VV) coding for several individual RSV proteins. We found that immunization with the different VVs yielded the following Tc memory cell populations: high levels of RSV-specific Tc cells were induced with the fusion protein VV, but low levels were induced with VV coding for the RSV nucleoprotein. Tc cell recognition of attachment glycoprotein, part of the matrix molecule or 1A internal protein was poor. While high levels of fusion protein-specific Tc cells were induced by the fusion protein VV, they showed poor cross-reactivity between the A2 and 8/60 RSV strains compared with Tc cells primed by RSV infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497222     DOI: 10.1099/0022-1317-68-8-2177

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  39 in total

1.  Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells.

Authors:  J L Muñoz; C A McCarthy; M E Clark; C B Hall
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

3.  Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus.

Authors:  R A Olmsted; B R Murphy; L A Lawrence; N Elango; B Moss; P L Collins
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

Review 4.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 5.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

6.  The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.

Authors:  P J Openshaw; K Anderson; G W Wertz; B A Askonas
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

7.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

8.  Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.

Authors:  A H Cherrie; K Anderson; G W Wertz; P J Openshaw
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

10.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.